Trial Profile
A phase III clinical trial comparing disease free survival between the combination of capecitabine and oxaliplatin (XELOX) versus the combination of fluorouracil (5FU)/leucovorin (LV) and oxaliplatin (FOLFOX) as an adjuvant therapy in patients with operated colorectal cancer of stages B2 (high risk) and C (according to Duke's)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 13 Jul 2011 New trial record